An invention from Purdue University innovators may provide a new option to use directed energy for biomedical and defense applications.
The Purdue invention use
E-Mail
WEST LAFAYETTE, Ind. - An invention from Purdue University innovators may provide a new option to use directed energy for biomedical and defense applications.
The Purdue invention uses composite based nonlinear transmission lines (NLTLs) for a complete high-power microwave system, eliminating the need for multiple auxiliary systems. The interest in NLTLs has increased in the past few decades because they offer an effective solid-state alternative to conventional vacuum-based, high-power microwave generators that require large and expensive external systems, such as cryogenic electromagnets and high-voltage nanosecond pulse generators.
NLTLs have proven effective for applications in the defense and biomedical fields. They create directed high-power microwaves that can be used to disrupt or destroy adversary electronic equipment at a distance. The same technology also can be used for biomedical devices for sterilization and noninvasive medical treatments.
Neuroscience seminar highlights technologies for brain injuries, vaccine developments
The Purdue Center for Paralysis Research brings neurophysiological and engineering solutions to a trauma-themed seminar series, co-sponsored by Plexon. (Image provided)
WEST LAFAYETTE, Ind. – The same technology that helps treat traumatic brain injuries in athletes and soldiers may one day help doctors determine the effectiveness of vaccines on patients.
This technology is among the neuroscience innovations and research in the spotlight as Purdue University’s Center for Paralysis Research and Plexon Neurotechnology Systems present the Seminar for Neurotrauma and Diseases. The seminar series, which runs through April, features speakers from Purdue, Harvard Medical School and the medical industry.
New inhibitors may offer novel approach to treating deadly tuberculosis
Zhong-Yin Zhang, head of Purdue’s Department of Medicinal Chemistry and Molecular Pharmacology, developed highly potent and selective compounds for use in the treatment of tuberculosis. (Image provided)
WEST LAFAYETTE, Ind. – Purdue University innovators have developed highly potent and selective compounds for use in the treatment of tuberculosis, which is one of the top 10 causes of death worldwide.
The Purdue researchers developed a series of small molecule inhibitors to target one of the proteins critical for the survival of TB in infected macrophages. Protein tyrosine phosphates B (mPTPB) is a virulence factor of TB to subvert the host immune responses.
Listen to this article
WEST LAFAYETTE, Ind. â Purdue University innovators have developed highly potent and selective compounds for use in the treatment of tuberculosis, which is one of the top 10 causes of death worldwide.
The Purdue researchers developed a series of small molecule inhibitors to target one of the proteins critical for the survival of TB in infected macrophages. Protein tyrosine phosphates B (mPTPB) is a virulence factor of TB to subvert the host immune responses.
The Purdue research is published in the Journal of Medicinal Chemistry.
âThe death toll from TB is particularly high because of drug-resistant strains,â said Zhong-Yin Zhang, distinguished professor and head of Purdueâs Department of Medicinal Chemistry and Molecular Pharmacology and director of Purdue Institute for Drug Discovery. âThese inhibitors are part of a promising new approach to developing TB therapeutic agents with novel targets and mechanisms of action to help save